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ackground to the debate: Isotretinoin is an effective 
treatment for severe acne, a condition which can be 
physically, emotionally, and socially disabling. Because the 
drug is teratogenic, causing severe birth defects, women 
taking the drug are directed to avoid pregnancy. In the 
United States, a series of risk reduction programs have 
been implemented that aim to prevent pregnant women 
from taking the drug and to prevent women taking it from 
getting pregnant. The most recent, and most stringent, is an 
Internet-based, performance-linked system called iPLEDGE, 
which tries to ensure that the drug is dispensed only when 
there is documentary proof that the patient is not pregnant 
and is using two forms of birth control. Is iPLEDGE the best 
way to reduce isotretinoin birth defects, or is it an unproven 
and overly burdensome system?
Lorien Abroms, Edward Maibach, and Katherine 
Lyon-Daniel’s Viewpoint: The Case for 
Information and Performance-Linked Systems 
Untreated acne can be the cause of both signiﬁ  cant 
physical and psychological sequelae [1]. Untreated acne has 
been associated with difﬁ  culties in interpersonal relationships 
[2], poor employment prospects [3], and suicide [4]. But 
acne treatment itself can also cause harm.
Isotretinoin—which is effective in the treatment of 
severe recalcitrant nodular acne [5]—is highly teratogenic. 
Pregnancies exposed to isotretinoin are at signiﬁ  cant risk 
of serious malformations [6,7]. Since introduction of the 
drug in 1982, over 2,000 pregnancies have been exposed 
to isotretinoin, most resulting in spontaneous or elective 
abortions [8]. Other risks to patients from isotretinoin 
use include increased risk of depression and suicide, liver 
damage, and musculoskeletal symptoms [5,9]. 
Isotretinoin is widely prescribed: each year, over 1.4 million 
isotretinoin prescriptions are dispensed in the United States 
[10]. About half of all prescriptions go to females [8], most 
of whom are in their reproductive years [7]. Many of the 
prescriptions written for isotretinoin appear to be written “off 
label”—either as a ﬁ  rst-line treatment for severe acne [11] or 
as treatment for mild to moderate cases of acne [12]. 
A number of increasingly strenuous risk management 
programs (RMPs) have been implemented since 
isotretinoin’s introduction. These programs aim to prevent 
pregnant women from taking the drug and to prevent 
women taking it from getting pregnant. The newest of these 
programs, iPLEDGE (Figure 1), became mandatory in the US 
on March 1, 2006. This program represents the most rigorous 
risk management program in history for such a widely 
prescribed drug, involving patients, physicians, pharmacies, 
and wholesalers [13].
In this article we provide a brief history and analysis of 
isotretinoin RMPs implemented over the past 20 years 
(summarized in Table 1), which offer general lessons about 
the effective use of health information and performance 
requirements. Additionally, we discuss our concerns with the 
existing iPLEDGE program and provide some suggestions for 
improving it. 
The health and risk communication literature and the 
broader health behavior literature makes clear that provision 
of health information has value only to the extent that it is 
clearly delivered, understood, accepted, and remembered by 
members of its intended audience [14,15]. Even when these 
conditions are met, health information inﬂ  uences subsequent 
health actions only to the extent that recipients are motivated 
What Is the Best Approach to Reducing 
Birth Defects Associated with Isotretinoin?
Lorien Abroms, Edward Maibach, Katherine Lyon-Daniel, Steven R. Feldman
Funding: LA, EM, and KL-D state that they received no speciﬁ  c funding to write 
their viewpoint. SRF states that the Center for Dermatology Research is supported 
by an educational grant from Galderma Laboratories, L. P. The funder played no 
role in the preparation of his viewpoint.
Competing Interests: The authors have declared that no competing interests exist.
Citation: Abroms L, Maibach E, Lyon-Daniel K, Feldman SR (2006) What is the best 
approach to reducing birth defects associated with isotretinoin? PLoS Med 3(11): 
e483. doi:10.1371/journal.pmed.0030483
Copyright: © 2006 Abroms et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author 
and source are credited. 
Abbreviations: PPP, Pregnancy Prevention Program; RMP, risk management 
program; SMART, System to Manage Accutane Related Teratogenicity
Lorien Abroms and Edward Maibach are in the Department of Prevention 
and Community Health, School of Public Health and Health Services, George 
Washington University, Washington, D. C., United States of America. E-mail: lorien@
gwu.edu; emaibach@gwu.edu. Katherine Lyon-Daniel is at the National Center 
on Birth Defects and Developmental Disabilities, Centers for Disease Control and 
Prevention, Atlanta, Georgia, United States of America. E-mail: kdl8@cdc.gov. The 
ﬁ  ndings and conclusions in the viewpoint by LA, EM, and KL-D are those of the 
authors and do not necessarily represent the views of the Centers for Disease 
Control and Prevention. Steven R. Feldman is at the Center for Dermatology 
Research, Departments of Dermatology, Pathology, and Public Health Sciences, 
Wake Forest University School of Medicine, Winston-Salem, North Carolina, United 
States of America. E-mail: sfeldman@wfubmc.edu
The PLoS Medicine Debate discusses important but controversial issues in clinical 
practice, public health policy, or health in general.
doi:10.1371/journal.pmed.0030483.g001
Figure 1. The iPLEDGE Logo 
iPLEDGE is a “comprehensive program to help you get prepared, plan 
your treatments, and ensure you don’t get pregnant during the course of 
isotretinoin therapy” (https://www.ipledgeprogram.com). 
(Figure: Covance Inc.)PLoS Medicine  |  www.plosmedicine.org 1979
to comply, have a strong belief in their ability to perform the 
recommended behaviors (i.e., high self-efﬁ  cacy), and have 
the skills necessary to perform the behavior in real-world 
contexts [16,17]. To be effective, behavioral RMPs must 
ensure that all of these conditions are met, or they must have 
means to enforce the performance of the behavior. 
First-Generation Approach to Risk Management: 
1982–1987
Accutane, the ﬁ  rst approved form of isotretinoin, was brought 
to market by Hoffman-La Roche (Roche) in September 1982. 
Anticipating teratogenic effects based on animal research, 
Roche distributed the drug with a warning on its Food 
and Drug Administration (FDA)–approved professional 
package insert and a patient brochure which warned against 
pregnancy. 
By October 1983, Roche had received seven reports of 
Accutane-caused fetal malformations. Roche took steps to 
heighten the strength of the pregnancy warning: language 
about the drug’s teratogenic potential was placed in bold on 
the package insert; warning letters were sent to prescribers; 
and red warning stickers were sent to pharmacists and 
wholesalers to be placed on the drug bottles [18]. 
Second-Generation Approach to Risk Management: 
1988–2001
Reports of fetal malformations continued, leading the FDA 
in 1988 to call for a stronger RMP [19]. As a result, Roche 
developed the Pregnancy Prevention Program (PPP). PPP 
was a comprehensive educational program which included 
materials for the prescriber to use in counseling the female 
patient about the importance of avoiding pregnancy while 
taking Accutane. Changes in the labeling and packaging 
included the addition of an icon intended to communicate 
the need to avoid pregnancy and a “black box” warning on 
the package insert [20]. More signiﬁ  cantly, the program 
required that prescribing physicians make three risk 
management procedures mandatory for all female patients 
as a precondition for prescribing: the signing of a patient 
consent form, the taking of a pregnancy test seven days prior 
to beginning treatment, and the selection of two reliable 
forms of birth control (unless patients indicated that they 
were abstinent). While these procedures were labeled as 
“requirements” for prescribing Accutane on the package 
insert, no mechanism was put in place to enforce that they 
were carried out. To facilitate the program’s implementation, 
Roche provided prescribing physicians with forms and 
educational materials to use in counseling patients. 
A Roche-sponsored evaluation of the PPP program, 
which was based on a voluntary sample of female Accutane 
patients, found that 99% of patients recalled having been 
told to avoid pregnancy [7]. However, 36% of patients 
failed to receive a pregnancy test prior to starting therapy, 
and 15% did not recall being told to use birth control for 
one month prior to starting therapy [7]. The pregnancy 
rate was found to be 3.4 pregnancies per 1,000 courses of 
isotretinoin [7]. A later study found the pregnancy rate 
had been reduced to 2.8 per 1,000, still resulting in scores 
of exposed pregnancies each year [19]. In a separate study 
of 14 Accutane-exposed pregnancies, eight women were 
found to have used no contraception at all, and another ﬁ  ve 
used only one method, when two were recommended [21]. 
In evaluating the program’s success, the FDA concluded 
that the voluntary and information-based RMP was not 
sufﬁ  ciently effective in inﬂ  uencing the contraceptive 
behavior of female patients and in reducing the number of 
exposed pregnancies [22].
Third-Generation Approach to Risk Management: 
2002–2005
In 2002, the FDA called for further revisions to the risk 
management program for Accutane and other more recently 
approved generic versions [22]. The FDA mandated that a 
medication guide —a written drug information sheet—be 
Table 1. Overview of History of Isotretinoin (Accutane) Risk Management Approaches
Risk Management Approach Original Warning 
(1982)
Revised Warning 
(1983)
PPP (1988) SMART (2001) iPLEDGE (2006)
Warning on label XXXXX
Red label stickers to pharmacies XXXX
“Avoid pregnancy” icon XXX
Patient consent form XXX
Required pregnancy test prior to start of 
treatment a
XXX
Required selection of two forms of birth control a XXX
Required two pregnancy tests prior to start of 
treatment a
XX
Pharmacists required to give medication guide 
with prescription
XX
Required use of qualiﬁ  cation stickers by 
registered prescribers a
X
Required monthly pregnancy tests a X
Required registration in database by patients, 
prescribers, pharmacists, and wholesalers a
X
Qualifying questions for patient X
Monthly identiﬁ  cation of contraceptive methods 
by patients and doctors
X
a As noted on prescription package insert. 
doi:10.1371/journal.pmed.0030483.t001
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given to patients by pharmacists along with all new and reﬁ  ll 
prescriptions of isotretinoin. Building on its PPP, Roche 
created SMART (System to Manage Accutane Related 
Teratogenicity), which upgraded the risk management 
practices to include improved education for female patients 
and two negative pregnancy tests. It also included a novel risk 
management tool: the required use of a yellow qualiﬁ  cation 
sticker on all prescriptions issued. The qualiﬁ  cation stickers—
which were to be ﬁ  lled out by prescribers and placed on 
prescriptions—were intended to serve as a reminder to 
prescribers of their responsibilities in insuring that female 
patients were qualiﬁ  ed for isotretinoin (i.e., that they had 
been given two pregnancy tests and found not to be pregnant, 
and that they had chosen two forms of birth control). While 
prescribers were sent the qualiﬁ  cation stickers only after 
signing a letter which detailed qualiﬁ  cation requirements, 
no enforcement mechanism was put in place to insure that 
prescribers gave qualiﬁ  cation stickers only to patients who 
were truly eligible. Pharmacists were required to ﬁ  ll only 
those Accutane prescriptions with an afﬁ  xed sticker [22]. All 
of the generic manufacturers ﬁ  elded similar risk management 
programs. 
An evaluation of the SMART program found that 98% 
of women taking Accutane knew to avoid pregnancy [23] 
and 92% recalled having received a prescription with a 
qualiﬁ  cation sticker [22]. However, of women at risk for 
pregnancy, 34% failed to receive the required two pregnancy 
tests [22]. Of women who were at risk for pregnancy and 
non-abstinent, 54% did not use two forms of birth control 
[22]. More importantly, the pregnancy rate did not decline 
substantially below that achieved under the PPP [22]. Thus, 
while the inclusion of a reminder system—the use of the 
yellow qualiﬁ  cation stickers—did increase the proportion of 
women who took pregnancy tests and used appropriate birth 
control [22], these changes fell short of expectations and did 
not lead to a sufﬁ  cient reduction in the number of exposed 
pregnancies. Although the evaluations of this RMP were not 
able to pinpoint the reasons for shortcomings in the system 
performance, prescriber under-compliance with qualiﬁ  cation 
requirements and patients’ lack of motivation, self-efﬁ  cacy, 
and/or ability to use two forms of contraception throughout 
the course of treatment were likely contributors. 
Fourth-Generation Approach to Risk Management: 
2005–Current
SMART’s limited success in further reducing isotretinoin-
exposed pregnancies led the FDA to request that Roche and 
other isotretinoin manufacturers create a more rigorous 
performance-linked RMP. Stringent performance-linked 
programs have been used for a handful of drugs including 
thalidomide and clozapine, though none of these are as 
widely prescribed as isotretinoin. In response to the request, 
all four manufacturers collaborated to create the iPLEDGE 
program. 
iPLEDGE requires that all parties in the distribution chain 
(i.e., health-care professionals who prescribe isotretinoin, 
pharmacies that dispense isotretinoin, and wholesalers 
that distribute isotretinoin) and all patients receiving 
prescriptions—male and female—register in a single database 
online (https:⁄⁄www.ipledgeprogram.com) or by telephone. 
Prior to dispensing to females, providers must enter the 
results of two negative pregnancy tests, and specify two forms 
of contraception that the patient agrees to use, and must on 
a monthly basis administer and verify the negative results of 
pregnancy tests, provide additional pregnancy prevention 
counseling, and re-identify the patient’s contraceptive 
choices. Prior to receiving their medication, patients must 
register with the system, sign a consent form, and identify 
their two forms of birth control. On a monthly basis, they 
must indicate their two forms of contraception (which must 
match the provider’s entry) and must answer questions which 
demonstrate their knowledge of the teratogenic effects of 
isotretinoin. Pharmacists are permitted to dispense only if the 
web-based system shows that the patient and provider have 
complied with all requirements of the system.
As the program is relatively new, there has been no formal 
evaluation of iPLEDGE to date. According to FDA reports, 
the program appears to have been widely adopted. Between 
December 30, 2005 and March 23, 2006, 22,000 prescribers 
and 71,700 patients registered with iPLEDGE [13]. However, 
based on news reports, the program has not been well 
received, especially by dermatologists, the primary prescribers 
of isotretinoin [24]. Dermatologists have complained that the 
new program is inﬂ  exible and confusing, and has too many 
requirements. Many were frustrated initially by technical 
glitches from the Web-based system coupled with inadequate 
telephone support [24]. There have also been reports of 
patients having difﬁ  culty in complying with the system’s 
numerous requirements [25].
The Advantages of iPLEDGE 
iPLEDGE has the potential to improve upon the previous 
RMPs by identifying existing pregnancies before treatment 
has begun, by detecting new, unplanned pregnancies earlier, 
and by increasing patients’ knowledge and motivation about 
the importance of complying with program requirements. 
Under iPLEDGE, prescribers must ensure two negative 
pregnancy tests before a patient can start treatment. This 
represents a signiﬁ  cant improvement because under SMART, 
over one-third of women did not receive these tests [22], and 
an estimated 13% of exposed pregnancies existed prior to 
the start of treatment [26]. Furthermore, requiring monthly 
pregnancy tests, pledging in advance to use two forms of 
birth control, and the myriad monthly reminders received 
by both patients and prescribers when they log onto the 
iPLEDGE system should have a beneﬁ  cial effect on a patient’s 
motivation to comply.
Effective use of contraception requires knowledge, 
motivation, skill, and for some methods, a high degree 
of self-efﬁ  cacy [27]. Under SMART, the most commonly 
reported reasons for pregnancy during isotretinoin therapy 
were unsuccessful attempts at abstinence, use of ineffective 
contraception, inconsistent use of contraception, unexpected 
sexual activity, and contraceptive failure [20]. It remains 
an open question the degree to which iPLEDGE will result 
in better pregnancy prevention skills, higher levels of 
self-efﬁ  cacy about pregnancy prevention and, ultimately, 
pregnancies prevented.
iPLEDGE represents the most rigorous 
risk management program in history 
for such a widely prescribed drug.
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Concerns about iPLEDGE
Despite the advantages of iPLEDGE, we have several 
concerns about the new program. Some patients who have 
insufﬁ  cient skills in using contraceptives will be in the care 
of providers (in most cases dermatologists) who may not 
have time or sufﬁ  cient knowledge to counsel their patients 
about contraceptive use. Some patients, especially teenagers, 
who represent a signiﬁ  cant proportion of isotretinoin users, 
will be unwilling to communicate openly with their health-
care provider about their sexual activity [22]. Some patients 
are likely to be insufﬁ  ciently motivated to follow through 
with their plans to use two forms of contraception for every 
sexual episode over a ﬁ  ve to six month course of treatment. 
Furthermore, as isotretinoin remains widely available over the 
Internet without a prescription [28], many people will obtain 
isotretinoin outside of the iPLEDGE RMP. This problem may 
increase as people try to avoid the stringent requirements that 
are part of iPLEDGE. 
Also of concern is that the iPLEDGE program may have 
been suboptimally designed, and as a result, may place 
an unnecessary burden on patients and providers. Core 
principles of program design and development dictate that: 
(1) programs should be developed with much input from the 
end-users of the systems—in this case prescribers, patients, 
pharmacies, and wholesalers; (2) programs should receive 
extensive user testing before being released to the public; 
and (3) programs should be developed and maintained 
within a context of total quality management [29]. These 
basic principles appear to have been somewhat violated in the 
development of iPLEDGE. 
Prior to the program’s release, limited input was solicited 
from the iPLEDGE Scientiﬁ  c Advisory Board, a group formed 
in early 2005 to represent the various stakeholder groups. 
The program became mandatory before it was sufﬁ  ciently 
tested, and users who were required to use the system were 
initially faced with navigating through technical problems 
and computer glitches [24]. It remains to be seen the degree 
to which principles of total quality management—including 
a strong focus on process measurement and continuous 
improvements—will be embraced.
Ways to Improve iPLEDGE
We see several opportunities to improve iPLEDGE to address 
some of these concerns. The fact that iPLEDGE is managed 
primarily via a Web site presents excellent opportunities for 
tailored and multimedia patient education that currently 
have not been embraced. As designed, the Web site’s 
primary function is data entry. The site currently contains 
a minimal amount of patient education material, and the 
information present is exclusively text-based, presented in 9 
point font, and written at a 12th grade reading level, which is 
substantially higher than the ability of the average adult [30]. 
We recommend the addition of appropriate multimedia 
educational content to: (1) reinforce important information 
(i.e., the risks associated with isotretinoin and the need for 
two forms of contraception), and perhaps more importantly, 
(2) provide an effective means of conveying difﬁ  cult or 
sensitive information that is not otherwise being effectively 
communicated (e.g., information on various contraceptive 
methods and how to appropriately use them, complete with 
animation/video to model various techniques). Furthermore, 
we recommend audience testing the Web site with all 
categories of users—current isotretinoin patients, prescribers, 
and pharmacists—to ensure that the content of the Web site 
is clearly communicated, easy to use, and meaningful. It may 
also be necessary to simplify the program requirements so 
that there is less burden on patients and providers, and less 
incentive for patients to circumvent program procedures. 
The required monthly knowledge-check questions in 
iPLEDGE—intended to determine if the patient understands 
the need for two forms of birth control and the potential of 
isotretinoin to cause birth defects—is a novel approach to 
encouraging patient compliance. However, given that nearly 
all patients said they understood they were not supposed 
to get pregnant under the previous RMPs [8,22,23], a 
more appropriate focus for these questions is to ensure 
that patients have actionable knowledge about pregnancy 
prevention and are properly using the contraceptive 
methods that they selected. Incorrect responses should elicit 
presentation of appropriate educational material.
By adding an e-mail function, iPLEDGE could 
automatically generate and send tailored reminders and 
other relevant information to patients. (For phone users, 
this information could be available via regular mail). Such 
proactive contacts might be especially valuable in reminding 
patients of the need for pregnancy prevention during the one 
month interval after therapy ends when many patients will 
lose contact with iPLEDGE. Under SMART, 32% of Accutane-
exposed pregnancies occurred during this post-therapy 
period [26]. 
We believe an important general lesson from evaluations 
of isotretinoin RMPs is that RMPs need to be designed with 
input from users in all phases of a program’s development. 
Furthermore, information alone may not be sufﬁ  cient 
to manage behavior-based medical risks, especially when 
mitigating those risks requires that the behaviors be performed 
consistently, and with considerable motivation and skill, 
over long periods of time. Having program “requirements” 
in the absence of enforcement mechanisms for those 
requirements may not be sufﬁ  cient to manage these types of 
medical risks. Finally, information and performance-linked 
approaches should not been seen as either/or alternatives, but 
complements in achieving sustained behavior change. 
The Case for Performance-Linked Systems
While performance-linked systems undoubtedly place a 
burden on everyone in the system, from a risk management 
perspective, there is a compelling case to be made for them. 
For example, Directly-Observed Treatment Short-Course 
(DOTS) has become the internationally recommended 
tuberculosis control strategy despite the demands it places 
on patients and the health-care system. The performance of 
iPLEDGE will likely inﬂ  uence a dialogue about whether the 
demands it places on patients and the health-care system are 
tolerable, and whether performance-linked systems should be 
extended to other medications when the potential negative 
consequences to patients, their offspring, or society at large 
are severe. 
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Steven R. Feldman’s Viewpoint: A Balanced 
Approach May Be The Best Way To Reduce 
Isotretinoin Birth Defects
Acne can disﬁ  gure patients physically and emotionally, 
while disabling them socially. This inﬂ  ammatory disease can 
have a dramatic impact on patients’ lives [31]. In the not-
too-distant past, there was little dermatologists could do for 
patients with the most severe forms. Now, patients (and their 
parents) do not need to suffer the physical and emotional 
scars of acne. For even the most severely affected patients, the 
disease is treatable, even curable, with isotretinoin. 
Unfortunately, isotretinoin is not without side effects. 
Patients must be warned about the rare risk of severe 
depression. While I am convinced this rare side effect is real, 
isotretinoin probably prevents more depression in teens than 
it causes [32,33]. More important is the risk of birth defects 
occurring when a fetus is exposed to isotretinoin. Isotretinoin 
is a powerful teratogen used in the treatment of a disease that 
occurs in young women of child-bearing potential. Physicians, 
and these patients, bear a heavy responsibility when using 
isotretinoin.
Under guidance from the FDA, isotretinoin manufacturers 
have instituted increasingly stringent programs to prevent 
isotretinoin-exposed pregnancies. Whether any of these 
programs have substantially reduced isotretinoin-exposed 
pregnancies beyond the efforts already taken by physicians in 
the care of their patients is not known [34]. It is difﬁ  cult for 
me to believe that any one-size-ﬁ  ts-all program could be more 
effective in preventing pregnancy than the careful efforts of 
a physician working with their patient. But when it comes to 
preventing birth defects, I’m glad for any help I can get. 
Unfortunately, we don’t know whether even the most 
stringent pregnancy prevention program so far, iPLEDGE, 
reduces the rate of exposed pregnancies. The pregnancy 
prevention programs have been based largely on monthly 
pregnancy testing. The history of the isotretinoin pregnancy 
prevention programs and a recent retrospective study show 
that pregnancy testing doesn’t prevent pregnancy [35]. I 
sometimes wonder if doing this testing gives some patients a 
cavalier attitude based on the false impression that catching 
pregnancies early will prevent isotretinoin-induced birth 
defects. Catching an exposed pregnancy early does not 
prevent isotretinoin teratogenicity. It is essential to make sure 
patients don’t get pregnant in the ﬁ  rst place.
One strength of iPLEDGE is accountability. At the very 
least, iPLEDGE will help prevent the 13% of exposed 
pregnancies that occur when someone who was already 
pregnant takes the drug. But iPLEDGE also has many 
weaknesses. The program was implemented without any 
testing to determine whether it actually reduces pregnancy 
risk. Beyond that, the hassles of the program leave less time 
to focus on the single most important message: you must not 
become pregnant while isotretinoin is in your body.
The apparently untested recommendations for improving 
iPLEDGE described by Abroms et al. may help, but they 
may not. A lesson from the history of past programs is that 
new programs should be tested before implementation. 
Until then, physicians must continue to use isotretinoin 
with great caution. Isotretinoin should be a last-line acne 
treatment for women of child-bearing potential. Typically, 
these women should ﬁ  rst be treated with a combination 
of topical antibiotics and retinoids [36], oral antibiotics 
(probably a second one if the ﬁ  rst doesn’t work), and birth 
control pills for several months before using isotretinoin. 
Birth control pills are an effective, FDA-approved treatment 
for acne in women. By using them ﬁ  rst, some isotretinoin use 
might be averted altogether. If isotretinoin is still necessary, 
the woman will already have been on birth control pills for 
several months and will have had time for education about 
the drug and proper (and, we all hope, effective) pregnancy 
prevention counseling. 
When treating a patient with severe acne unresponsive to 
other treatments, having access to isotretinoin is a godsend. 
Perhaps some people believe that even one isotretinoin-
induced birth defect is too many and think that isotretinoin 
use should be stopped altogether. Stopping birth defects 
is an emotionally powerful goal. Yet dermatologists often 
see patients with horriﬁ  c scars from acne, patients whose 
suffering could have been prevented by early treatment with 
isotretinoin. 
There are both risks and beneﬁ  ts to isotretinoin. There 
has been some effort to quantify and compare these risks 
and beneﬁ  ts [37]. Despite patients’ and physicians’ efforts at 
pregnancy prevention, there are still a limited number of fetal 
isotretinoin exposures. Yet because acne is so horriﬁ  c and 
so common, even the most conservative risk/beneﬁ  t analysis 
ﬁ  nds that, overall, isotretinoin provides far more beneﬁ  t 
than risk. Even if it were used for milder forms of acne, the 
beneﬁ  ts accrued to society from using isotretinoin outweigh 
the risks in quantitative analyses. While everyone (patients, 
their families, physicians, the media, interest groups, and 
politicians) would like to see the risk of isotretinoin-induced 
birth defects reduced to the lowest possible level, those who 
see the beneﬁ  ts of isotretinoin do not want patients to suffer 
(and suffer greatly) by losing isotretinoin entirely.
The beneﬁ  ts accrued to society from 
using isotretinoin outweigh the risks.
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